Adaptimmune

  • Home
  • Our Company
    • Overview arrow_forward
    • Board of Directors arrow_forward
    • Leadership Team arrow_forward
  • Products
  • Pipeline
    • Overview arrow_forward
    • Afami-cel arrow_forward
    • Lete-cel arrow_forward
    • Uza-cel arrow_forward
  • Technology
    • Overview arrow_forward
    • Manufacturing arrow_forward
    • Publications arrow_forward
  • Patients & Families
    • Overview arrow_forward
    • Taking Part in Our Clinical Trials arrow_forward
    • Videos arrow_forward
  • Clinical Trials
    • Overview arrow_forward
    • Expanded Access Policy arrow_forward
  • Investors & Media
    • Overview arrow_forward
    • News Center arrow_forward
    • Financial Info and Governance arrow_forward
    • Stock Data arrow_forward
    • SEC Filings arrow_forward
  • Contact
  • Careers
    • Overview arrow_forward
    • US Careers arrow_forward
    • UK Careers arrow_forward

Press Releases

Investors & Media

Investors & Media

  • Overview
  • News Center
    • Media Resources
    • Corporate Presentations
    • Press Releases
    • Publications
    • Events
    • Email Alerts
  • Financial Info and Governance
    • General Meeting (merger)
    • Company Information
    • Leadership Team
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Annual Shareholder Meeting
    • FAQ
    • Contacts
    • Adaptimmune Ltd Report
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • News Center

  • Media Resources
  • Corporate Presentations
  • Press Releases
  • Publications
  • Events
  • Email Alerts
May 01, 2024 12:00pm EDT

Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

Apr 12, 2024 8:00am EDT

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Mar 27, 2024 7:30pm EDT

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Mar 06, 2024 7:00am EST

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

Feb 27, 2024 8:00am EST

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Feb 21, 2024 4:00pm EST

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

Jan 31, 2024 4:44pm EST

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Jan 04, 2024 7:37am EST

Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference

Dec 06, 2023 7:00am EST

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

Nov 29, 2023 8:00am EST

Adaptimmune Receives Transfer of IND for Lete-cel Program

RSS
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...29
  • Next
Adaptimmune
Disclosures Privacy Policy Disclaimer Search Sitemap Terms of Use Supply Terms Cookie Policy Manage Cookie Preferences
Linedin Twitter Youtube
© 2025 Adaptimmune. All Rights Reserved.